전사체학 시장 : 시장 규모, 점유율, 동향 및 예측 - 유형별, 기술별, 용도별, 최종 사용자별, 지역별(2026-2034년)

The global transcriptomics market size was valued at USD 8.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 12.7 Billion by 2034, exhibiting a CAGR of 5.08% from 2026-2034. North America currently dominates, with 37.7% of the total transcriptomics market share. The demand in the region is driven by continuous advancements in genomic research, increasing adoption of personalized medicine, strong funding for healthcare research, and the presence of key market players.

Transcriptomics is the study of the allocation of ribonucleic acid (RNA) transcriptions initiated through the genotype of any determined object at an offered time, under certain conditions, or at a particular cell. It links the genome, the proteome, and the cellular phenotype. Transcriptomics encompasses RNA transcription and expression levels, functions, locations, trafficking, and degradation. Transcriptomics employs microarray hybridization, real-time quantitative polymerase chain reaction (Q-PCR), and next-generation sequences to identify the transcriptional architecture of a gene. It also assists researchers in characterizing transcriptional activity, focuses on a subset of relevant target genes and transcripts, and identifies genes and pathways that respond to and counteract biotic and abiotic environmental stresses.

The transcriptomics market demand is driven by the ongoing advancements in next-generation sequencing (NGS) technologies that have enhanced the accuracy and efficiency of gene expression analysis. In addition, the rising demand for personalized medicine is encouraging the use of transcriptomics to identify biomarkers for targeted therapies, aiding the market growth. Moreover, the increasing investments in genomic research by government and private entities are fueling innovation in the field, thus contributing to the market expansion. For instance, in January 2025, Truveta entered into a $320 million funding agreement for the building of what will be the largest public genomic database in the world at 10 million genomic sequences. This involves investors such as Regeneron Pharmaceuticals and Illumina and aims at surpassing the discovery of drugs and correspondent care of patients by detecting genetic tendencies or disease mutations. Furthermore, collaborations between academia and industry are fueling product development and commercialization, thus catalyzing the market growth.

The United States holds 82.90% of the market share. The transcriptomics market growth in this region is propelled by a robust healthcare infrastructure that supports advanced research and development (R&D). In line with this, the growing focus on precision agriculture and plant genomics is expanding transcriptomics applications in agrigenomics, fostering market demand. Concurrently, the rising public and private funding for rare disease research is driving the demand for innovative transcriptomic tools. Additionally, the increasing utilization of single-cell transcriptomics in immunology and oncology is fostering growth. For example, Illumina collaborated with the Broad Institute to design new gene sequencing kits employing CRISPR technology in PerturbSeq screening. Such a partnership is expected to enhance large-scale gene sequencing, which has a dramatic effect on disease and treatment modeling. Moreover, the strong presence of cutting-edge biopharmaceutical companies is boosting the adoption of transcriptomic technologies and strengthening the market share. Apart from this, increasing government initiatives promoting biotechnology and genomics education are cultivating a skilled workforce, thereby propelling the market forward.

TRANSCRIPTOMICS MARKET TRENDS:

Integration of Transcriptomics with ML and AI

According to the transcriptomics market forecast, the incorporation of machine learning (ML) and artificial intelligence (AI) is anticipated to revolutionize data analysis in this field. AI-powered tools can effectively interpret large datasets, diagnosing complicated correlations as well as patterns in gene expression. According to research article published in the journal Nature Methods in February 2024, researchers at the University of Toronto have developed a single-cell generative pre-trained transformer (scGPT), an innovative AI model that can efficiently predict the impacts of manipulating specific genes and can integrate different batches of data to detect otherwise untraceable cell types. Moreover, this approach bolsters disease comprehension, drug discovery, and biomarker identification. In addition, machine learning models can project disease outcomes based on transcriptomic data, significantly improving personalized medicine. As the intricacy of transcriptomic data elevates, ML and AI are rapidly becoming requisite for acquiring meaningful insights, positioning this integration as a key trend driving the transcriptomics market growth significantly. Furthermore, the accelerating adoption of AI and ML in transcriptomics is anticipated to boost advancements in precision medicine and targeted therapies, enabling more precise and faster identification of disease mechanisms and novel therapeutic targets.

Advancements in Single-Cell Transcriptomics

The development of single-cell transcriptomics has revolutionized the global transcriptomics market by facilitating the comprehensive study of gene expression at the individual cell level. This trend is rapidly gaining momentum as researchers are actively seeking ways to interpret cellular heterogeneity in various diseases such as neurological disorders and cancer. The growing prevalence of cancer further fuels this trend, as single-cell transcriptomics is requisite for understanding tumor complexity and developing personalized treatments, resultantly contributing to the expansion of transcriptomics market share. According to industry reports, more than 1.9 million new cancer cases were projected to be diagnosed in the U.S. in the year 2023, with 609,820 estimated deaths. Furthermore, single-cell analysis provides an accurate interpretation of cell behavior, resulting in the discovery of innovative biomarkers and new therapeutic targets. In addition, with increasing enhancements in technology and significant reductions in costs, the need for single-cell transcriptomics is substantially accelerating, bolstering the market expansion in both clinical applications and academic research activities.

Increasing Application in Personalized Medicine

The growing integration of transcriptomics in clinical research is transforming treatment protocols across healthcare sectors. The transcriptomics market analysis indicates that this field of study is rapidly being applied in personalized medicine, where comprehending individual gene expression profiles contributes to tailoring treatment methodologies. This trend is primarily propelled by the escalating interest in precision healthcare, especially in rare disorders and cancer. As per industry reports, functional precision medicine can effectively identify effective treatments for almost 55% of adult patients with blood cancers, including lymphoma and leukemia, who have not responded to conventional treatment methods. Moreover, by locating patient-specific biomarkers, transcriptomics facilitates the development of targeted therapies and minimizes the risk of adverse drug reactions. As a result, several healthcare providers as well as pharmaceutical firms are increasingly adopting transcriptomic techniques to formulate individualized treatment strategies. Furthermore, as personalized medicine becomes more prevalent, this field is anticipated to play a crucial role, spurring the demand globally and contributing to a positive transcriptomics market outlook.

Growing Use in Diagnostics and Disease Profiling

The global transcriptomics market is experiencing growth, significantly influenced by the increasing role of transcriptomics in diagnostics and disease profiling, especially in understanding tumor heterogeneity and cancer cell populations. Transcriptome analysis allows researchers to explore the molecular basis of cancer and provides information on tumor progression. Transcriptomic technologies are broadening knowledge about carcinogenesis, the tumor microenvironment, and immuno-oncology, as well as enabled the discovery of new cancer biomarkers. Furthermore, transcriptomic strategies are seeing wide usage in various fields of biomedical research, like disease diagnosis and profiling. RNA-Seq methods enable the extensive identification of transcriptional start sites, reveal alternative promoter utilization, and uncover new splicing changes. In 2024, J INTS BIO announced the launch of an AI-driven alliance to advance cancer therapy. This collaboration, which incorporated transcriptomics along with other multi-omics technologies, aimed to develop personalized lung cancer treatments through AI, enhancing drug efficacy prediction and reducing toxicity.

TRANSCRIPTOMICS INDUSTRY SEGMENTATION:

Analysis by Type:

• Instruments
• Consumables
• Software
• Services

Consumables represent the leading segment in the transcriptomics market with 43.8% shares, driven by their essential role in every phase of transcriptomic research. This category includes reagents, kits, probes, and microarrays, which are indispensable for sample preparation, gene expression analysis, and validation. Similarly, the flow of consumables has been triggered by high-throughput sequencing, real-time PCR, and many others all of which require many consumables. Moreover, as the rate of genetic and chronic diseases is on the rise, more research is being carried out which has promoted the recurrent purchase of consumables. The market has also contributed to the growth of the segment because of more efficient kits and reagents for single-cell transcriptomics technology. Besides this, the enhancement in opportunities for personalized medicine and biomarker identification also guarantees the steady growth of consumables' demand in the future.

Analysis by Technology:

• Microarray
• Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
• Sequencing Technologies

Real-Time Quantitative Polymerase Chain Reaction (Q-PCR) is a leading technology segment in the transcriptomics market due to its unparalleled sensitivity, specificity, and quantification capabilities in gene expression analysis. As a fast and convenient method for confirming data produced by high-throughput sequencing and microarray analysis, Q-PCR is an essential tool of transcriptomics studies. The ability to sample different types as a norm besides the ability to analyse single cells up to tissues also puts the technology in a pole position. Furthermore, heel growth in clinical diagnostics particularly for cancer biomarkers, infective agents, and genetic disorders will augment market growth. Also, constant improvements in Q-PCR reagents, automation procedures, and high throughput platforms have pushed forward the efficiency and reliability of the technique so that it remains a favored technology in the transcriptomics arena.

Analysis by Application:

• Diagnostics and Disease Profiling
• Drug Discovery
• Others

Drug discovery is a leading application segment, accounting for 33.8% of the market shares, driven by the growing need for precision medicine and innovative therapeutics. Transcriptomics is a key approach for the discovery of new drugs and targets, disease characterization, and drug response prediction based on the measurement of gene expression. These technologies are used in pharmaceutical and biotechnology firms as a tool to enhance discovery and bring new products to market faster and for less money. The availability of such sophisticated approaches as RNA sequencing and single-cell transcriptomics has improved the reliability of target definition and biomarker identification. In addition, chronic diseases are increasing, and personalized medicine gets more investment to maintain the constant usage of transcriptomics in drug discovery.

Analysis by End User:

• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Others

Academic and research institutes drive the transcriptomics market through extensive basic and applied research on gene expression. Their focus on exploring disease mechanisms, biomarker discovery, and innovations in technology underpins the growth of this critical end-user segment.

Transcriptomics is employed by pharmacological industries in drug development, clinical tests, and individualized medicine. As these companies use transcriptomic tools to discover cure points and improve the effectiveness of a drug, they are contributing immensely towards the growth of the market and technology.

Biotechnology companies employ transcriptomics for innovative solutions in genomics, agrigenomics, and personalized medicine. Their focus on developing new products and applications, such as RNA-based therapeutics, drives technological progress, significantly boosting the transcriptomics market trends.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America dominates the market with 37.7% of the market share due to its advanced healthcare infrastructure, strong focus on R&D, and robust funding from the public and private sectors. In line with this, the region benefits from the presence of leading pharmaceutical, biotechnology, and genomic companies driving innovation in transcriptomic technologies. For instance, Illumina's partnership with the Broad Institute of MIT and Harvard to scale up single-cell sequencing has the potential to greatly boost North America's advantage in genomic research and personalized medicine. This partnership seeks to make high-capacity single-cell experiments become a reality using Illumina's Fluent instrumentality. Moreover, the growing emphasis on precision medicine and the rising incidence of chronic and genetic disorders are significant drivers propelling market expansion. Besides this, the availability of advanced bioinformatics tools and expertise enhances the analysis of transcriptomic data. Furthermore, government-backed initiatives, including investments in genomic research and educational programs, create a favorable landscape for market growth. Apart from this, the region's strong network of academic and research institutions also fosters continuous advancements in transcriptomics, solidifying North America's leadership position in the global market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES TRANSCRIPTOMICS MARKET ANALYSIS

The American Cancer Society reported that approximately 1.9 million new cancer cases were diagnosed in 2022, accompanied by 609,360 cancer-related deaths in the United States. The alarming prevalence demands advanced research tools, thereby fostering the growth of the transcriptomics market. As it gives insights into the gene expression pattern, transcriptomics plays a central role in the understanding of the molecular mechanisms related to cancer. This industry supports the identification of biomarkers to make a diagnosis of a disease earlier, track the progression of a disease, and create precise therapies. The need for accurate medicine is rising; therefore, this industry is indeed being contributed to by the federal government. In the National Cancer Institute, funding was USD 6.9 Billion in 2022, as per reports. Biopharmaceutical collaborations that are developing RNA-based cancer therapy are also driving this market. These all highlight the importance of transcriptomics in addressing the country's increasingly serious cancer burden.

EUROPE TRANSCRIPTOMICS MARKET ANALYSIS

EU4Health is described by the European Commission as the European Union's strategic response to the challenges thrown up by the COVID-19 pandemic to the healthcare systems, medical staff, and patients of Europe. It encompasses a wide program that aims to move beyond crisis management into building a stronger, healthier, and more resilient Health Union. As the biggest health initiative ever undertaken by the EU, EU4Health will dedicate more than Euro 5 Billion (USD 5.1 Billion) over seven years (2021-2027) to improving healthcare outcomes in the region. EU4Health's efforts to enhance healthcare infrastructure, coupled with promoting innovative research, will provide major growth opportunities in the transcriptomics market in Europe. Through funding advanced technologies and encouraging multi-state collaborative research, EU4Health is paving the way for the use of transcriptomic tools to understand and diagnose diseases more effectively and through personalized medicine. Such initiatives can be best aimed at combating complicated diseases such as cancer, rare genetic diseases, and chronic illnesses while ensuring Europe is a leader in innovative healthcare products.

ASIA PACIFIC TRANSCRIPTOMICS MARKET ANALYSIS

According to NCBI, cancer-related medical costs in Asia will be increased dramatically in the future. The projected increase is expected to be around JPY 686.4-1,104.2 Billion (USD 6.2-10.0 Billion) by FY 2050. This necessitates the high priority of this disease area for sustainable medical financing in the region. The increased costs underscore the need for innovative research tools, such as transcriptomics, to improve the efficacy of cancer diagnostics, treatment strategies, and drug development. The Asia-Pacific region is witnessing growth in healthcare infrastructure and government initiatives to address the growing burden of cancer. The high population density and increasing prevalence of chronic diseases in the region make transcriptomics a critical tool in advancing precision medicine and improving patient outcomes. China, India, and Japan are the driving countries for this movement, increasing investment in biotechnology research and linking academia with the industry. In that respect, Asia-Pacific represents a huge market for transcriptomics advancement.

LATIN AMERICA TRANSCRIPTOMICS MARKET ANALYSIS

The growing prevalence of cancer in Latin America, particularly in middle-income mixed-economy countries like Brazil, is a significant factor driving the region's transcriptomics market. In the last 15 years, Brazil has experienced a steady annual increase in cancer cases, from 472,050 in 2005 to 489,270 in 2010, 576,000 in 2015, and reaching 625,000 cases per year from 2020 to 2022, according to the American Society of Clinical Oncology (ASCO). This increasing incidence calls for more advanced molecular research tools, including transcriptomics, to enhance the diagnostic and treatment planning of cancer and drug development. Since the region's healthcare systems have put more focus on the growing burden of cancer, the adoption of transcriptomics in uncovering patterns of gene expression and promoting personalized medicine approaches is becoming important. Investments in research infrastructure and discussions with local institutions and global biotech firms are also in place to speed up the adoption of transcriptomics technologies. The demand for targeted therapies and better health outcomes places Latin America at the epicenter of emerging markets for transcriptomics innovation.

MIDDLE EAST AND AFRICA TRANSCRIPTOMICS MARKET ANALYSIS

The rapid advancement in health research happening in the UAE is a highly driving factor towards the growth in the transcriptomics market in the Middle East and Africa region. According to the Ministry of Health and Prevention report, the country has been witnessing a growth rate in its health research sector thrice as high compared to the global average; this even reached an astonishing 25.2% increase in research outputs from 2017 to 2022. This signifies an important strategic focus by the UAE on creating innovation and excellence in healthcare and biomedical sciences. The UAE has also emerged as a major GCC country collaborator in health research. About 80% of the health research published in the UAE is conducted in collaboration with international institutions, which reflects its commitment to global scientific cooperation. According to MoHAP, this collaborative environment is bolstering advancements in molecular and genomic research, including transcriptomics. Supported by strong government initiatives and partnerships, these efforts pave the way for better health solutions and innovative technology adoption in the region.

COMPETITIVE LANDSCAPE:

The transcriptomics market is highly competitive, driven by continuous innovation and strategic efforts from leading industry players. Companies are focusing on developing advanced technologies, such as single-cell transcriptomics and high-throughput RNA sequencing, to enhance data accuracy and efficiency. Strategic collaborations between pharmaceutical firms, biotechnology companies, and academic institutions are becoming increasingly common, fostering innovation and accelerating product development. Industry players are making significant investments in research and development to launch innovative consumables and software solutions designed for personalized medicine and drug discovery. Mergers, acquisitions, and strategic partnerships are key trends, allowing companies to broaden their portfolios and extend their global presence. Moreover, the integration of artificial intelligence and machine learning into transcriptomics is gaining momentum, further fueling market expansion.

The report provides a comprehensive analysis of the competitive landscape in the transcriptomics market with detailed profiles of all major companies, including:

• Agilent Technologies Inc.
• Becton Dickinson and Company
• BGI Group
• Bio-Rad Laboratories Inc.
• Biospyder Technologies Inc.
• Illumina Inc.
• Nanostring Technologies Inc.
• Qiagen
• Roche Holding AG
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transcriptomics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Instruments
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Software
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Services
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Microarray
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Sequencing Technologies
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Diagnostics and Disease Profiling
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Drug Discovery
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Academic and Research Institutes
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Pharmaceutical Companies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Biotechnology Companies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agilent Technologies Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Becton Dickinson and Company
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 BGI Group
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 Bio-Rad Laboratories Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Biospyder Technologies Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Illumina Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Nanostring Technologies Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
  • 15.3.8 Qiagen
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Roche Holding AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
  • 15.3.10 Takara Bio Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
  • 15.3.11 Thermo Fisher Scientific Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis